Inventiva lays off 50% of staff to go all-in on MASH drug
Inventiva is going all-in on its metabolic-associated steatohepatitis drug lanifibranor—but half of its employees won’t be coming along for the ride.
Inventiva is going all-in on its metabolic-associated steatohepatitis drug lanifibranor—but half of its employees won’t be coming along for the ride.
